Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 2/20 | 0.34 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.33 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22831947 | 0.89 | BRAF (0.33) | BRAFHSPB1ALDH3A1KMT2A | |
| SCHEMBL28706013 | 0.83 | BRAF (0.32) | BRAFHCAR3 | |
| SCHEMBL22831977 | 0.77 | BRAF (0.41) | BRAFALDH3A1HCAR3TDP1ALDH1A1 | |
| SCHEMBL22832041 | 0.76 | BRAF (0.34) | BRAF | |
| SCHEMBL29562007 | 0.75 | BRAF (0.33) | BRAFALDH3A1KMT2AALDH1A1MAPT | |
| SCHEMBL22831802 | 0.75 | BRAF (0.33) | BRAFALDH3A1KMT2AALDH1A1MAPT | |
| SCHEMBL27101321 | 0.74 | CA1 (0.32) | BRAF | |
| SCHEMBL28704274 | 0.74 | — | — | |
| SCHEMBL22832070 | 0.71 | ALDH1A1 (0.33) | HCAR3TDP1ALDH1A1MAPT | |
| SCHEMBL22831987 | 0.67 | BRAF (0.35) | BRAFKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634409-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | ARRAY BIOPHARMA INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220289721-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | ARRAY BIOPHARMA INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-11414404-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | ARRAY BIOPHARMA INC. (US) | 2022-08-16 | — | — | US | disclosed |
| EP-3990437-A1 | QUINAZOLIN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | Array Biopharma, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114026073-A | Quinazolin-4-one derivatives for the treatment of BRAF related diseases and disorders | ARRAY生物制药公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20200407344-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | ARRAY BIOPHARMA INC. (US) | 2020-12-31 | — | — | US | disclosed |
| WO-2020261156-A1 | QUINAZOLIN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | ARRAY BIOPHARMA INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407344-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | BRAF, NRAS, RAF1 | BRAF 1/4885HSPB1 2780/4885ALDH3A1 2711/4885 |
| US-11634409-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | BRAF, NRAS, RAF1 | BRAF 1/4885HSPB1 2780/4885ALDH3A1 2711/4885 |
| US-11414404-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | BRAF, NRAS, RAF1 | BRAF 1/4885HSPB1 2780/4885ALDH3A1 2711/4885 |
| US-20220289721-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | BRAF, NRAS, RAF1 | BRAF 1/4885HSPB1 2780/4885ALDH3A1 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.